Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer

As the predominant treatment option of the immunotherapy for advanced esophageal cancer (EC), the application of programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors brings new hope to clinical practice. However, a considerable portion of patients do not response to this therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Chao, Zhuge, Lingdun, Xiao, Xin, Luan, Siyuan, Yuan, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483164/
https://www.ncbi.nlm.nih.gov/pubmed/36132136
http://dx.doi.org/10.3389/fonc.2022.955163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483164/
https://www.ncbi.nlm.nih.gov/pubmed/36132136
http://dx.doi.org/10.3389/fonc.2022.955163

Ejemplares similares